Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-22-001572
Filing Date
2022-02-14
Accepted
2022-02-14 09:05:54
Documents
59
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q edsa_10q.htm   iXBRL 10-Q 533154
2 CERTIFIATION edsa_ex311.htm EX-31.1 10792
3 CERTIFIATION edsa_ex312.htm EX-31.2 10750
4 CERTIFIATION edsa_ex321.htm EX-32.1 3990
5 CERTIFIATION edsa_ex322.htm EX-32.2 4050
  Complete submission text file 0001654954-22-001572.txt   2950562

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA edsa-20211231.xsd EX-101.SCH 36758
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE edsa-20211231_lab.xml EX-101.LAB 218282
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE edsa-20211231_cal.xml EX-101.CAL 34877
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE edsa-20211231_pre.xml EX-101.PRE 177939
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE edsa-20211231_def.xml EX-101.DEF 69093
53 EXTRACTED XBRL INSTANCE DOCUMENT edsa_10q_htm.xml XML 382038
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Filer) CIK: 0001540159 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37619 | Film No.: 22625939
SIC: 2834 Pharmaceutical Preparations